Istradefylline - Isotope Labelled Standards
References
FAQ's
References
- Suzuki, Fumio; Shimada, Junichi; Koike, Nobuaki; Nakamura, Joji; Shiozaki, Shizuo; Ichikawa, Shunji; Nonaka, Hiromi, Therapeutic agent for Parkinson's disease, US5484920A, Jan 16,1996, Kyowa Hakko Kogyo Co., Ltd., Japan (https://patents.google.com/patent/US5484920A/en)
- Xu, Haojie; Wang, Yiyun; Wang, Hongyi; Zheng, Zhonghui; Meng, Zihui; Xue, Min; Xu, Zhibin, Separation and identification of an impurity from the Istradefylline intermediate, RSC Advances, Volume: 10, Issue: 25, Pages: 14493-14499, 2020 DOI: (10.1039/c9ra09074f)
Frequently Asked Questions
2.How do you identify the Istradefylline impurities?
HPLC and preparative HPLC help to identify the Istradefylline impurities.
3.How does the Istradefylline drug degrade?
Istradefylline degrades under light to an isomer, Z-Istradefylline.
4.Why is it necessary to control the Istradefylline impurities in the drug?
Istradefylline impurities can affect drug safety, quality, and efficacy. Because they may cause adverse effects, it is extremely necessary to control the impurities in the drug.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.